Healthcare company Luminex Corporation (NASDAQ:LMNX) reported on Thursday the receipt of USD5.39m to conduct product development work and complete a 510(k) filing for its expanded NxTAG Respiratory Pathogen Panel (RPP), including the SARS-CoV-2 virus for high-throughput COVID-19 testing and differentiate COVID-19 from current strains of other common respiratory illnesses, including flu.
The company received the USD5.39m funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services.
According to the company, the expanded NxTAG RPP combines the original NxTAG RPP, an FDA-cleared in vitro diagnostic for syndromic respiratory infection testing, with the most relevant circulating pathogen, SARS-CoV-2. It has submitted an Emergency Use Authorization (EUA) to the US FDA for the expanded test, which would allow clinical labs to use the panel prior to 510(k) clearance.
Following the addition of SARS-CoV-2, the expanded NxTAG RPP will provide scalable throughput, allowing clinical labs to run up to 96 samples at a time – generating results in approximately four hours with minimal hands-on time. The test will be run on the company's easy-to-use, compact MAGPIX System and is designed for use in high-complexity molecular laboratories.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data